Andere Sprachen Glaukos Corporation

Aktien

A14VCK

US3773221029

GKOS

Medizinische Versorgung

Markt geschlossen - Nyse Andere Börsenplätze 22:00:02 05.12.2025			% 5 Tage	Veränd. 1. Jan.
108,51 ^USD	-0,31 %		+2,09 %	-27,63 %

03.12.	Glaukos Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01:45 PM
21.11.	Glaukos-Insider verkauft Aktien im Wert von 1.740.600 US-Dollar, laut aktueller SEC-Meldung	MT

Andere Sprachen

Glaukos Insider Sold Shares Worth $1,740,600, According to a Recent SEC Filing	21.11.
Glaukos : Investor Presentation November 2025	10.11.
Glaukos Announces Participation in Upcoming Investor Conferences	03.11.
Traders Await More Big Tech Earnings as US Equity Futures Decline Pre-Bell	30.10.
Top Premarket Gainers	30.10.
Glaukos: Q3 Earnings Snapshot	29.10.
Medical device maker Glaukos posts smaller-than-expected loss in Q3 on strong demand in U.S.	29.10.
Glaukos : Third Quarter 2025 Press Release (URL)	29.10.
Glaukos : Third Quarter 2025 GAAP to Non-GAAP Recs	29.10.
Glaukos : Third Quarter 2025 Quarterly Summary	29.10.
Earnings Flash (GKOS) Glaukos Corporation Reports Q3 Revenue $133.5M, vs. FactSet Est of $122.4M	29.10.
Earnings Flash (GKOS) Glaukos Corporation Posts Q3 Adjusted Loss $0.16 per Share, vs. FactSet Est of $-0.26	29.10.
Glaukos Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	29.10.
Glaukos Announces Third Quarter 2025 Financial Results	29.10.
Glaukos Corporation Raises Revenue Guidance for the Year 2025	29.10.
Glaukos Corporation Provides Revenue Guidance for the Year 2026	29.10.
Sector Update: Health Care Stocks Advance Pre-Bell Monday	20.10.
Glaukos Says Drug Treating Keratoconus Receives FDA Approval	20.10.
US FDA approves Glaukos' new eye therapy	20.10.
Glaukos Announces FDA Approval of Epioxa™	20.10.
Glaukos Corporation Announces FDA Approval of Epioxa New Drug Application	20.10.
Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting	14.10.
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29	08.10.
Glaukos Starts Construction of $80 Million Manufacturing Site in Alabama	25.09.
Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama	25.09.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Glaukos Corporation

Aktien

A14VCK

US3773221029

GKOS

Medizinische Versorgung

Andere Sprachen

Filter